Developmental Dysplasia of the Hip in Infants: Prevalence and Risk Factors

Marcelo Ortega-Silva1,2, Pablo Navarro-Cáceres3,4, Mariano Del Sol1,5

  • 1Programa de Doctorado en Ciencias Morfológicas, Facultad de Medicina, Universidad de La Frontera, Temuco 4780000, Chile.

Insights

This study found a 12% prevalence of developmental dysplasia of the hip (DDH) in Chilean infants, higher than previously reported. Female infants and specific hip joint abnormalities were associated with increased DDH risk.

Area of Science:

  • Pediatric Orthopedics
  • Radiology
  • Public Health

Background:

  • Developmental dysplasia of the hip (DDH) affects 0.1%–3% of infants globally.
  • Chile exhibits a high incidence of DDH, with 1 in 500 live births.
  • Understanding DDH prevalence and risk factors is crucial for early intervention in infants.

Purpose of the Study:

  • To determine the prevalence of DDH in a Chilean infant population.
  • To investigate associations between DDH and identified risk factors.
  • To provide preliminary data for further research on DDH in South America.

Main Methods:

  • A single-center study involving 100 infants aged 90–150 days.
  • Pelvic radiographs were analyzed for DDH diagnosis.
  • Statistical analyses included normality tests, Chi-square, t-tests, Mann-Whitney U, and multivariate analyses for risk factor assessment.

Main Results:

  • The prevalence of DDH was found to be 12%, with a higher incidence in the left hip.
  • Female infants showed a greater frequency of DDH.
  • Significant associations were observed with hip abduction asymmetry (p=0.023), acetabular roof obliquity (p=0.003), left hip involvement (p=0.002), and infant height at two months (p=0.016).

Conclusions:

  • The study identified a higher DDH prevalence in Chilean infants than previously documented.
  • Findings align with existing literature regarding the higher prevalence of DDH in female infants.
  • The results underscore the need for targeted screening and management strategies for DDH in the region.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...